← All trials
NCT07294950
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2026
- Primary completion
- Sep 30, 2028
- Completion date
- May 31, 2029
- First posted
- Dec 19, 2025
- Last posted
- Dec 19, 2025
- Enrollment
- 98
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of TorontoLead sponsor
- Heart and Stroke Foundation of CanadaCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.